Our Pipeline

A core dependency in prostate cancer, lymphomas, and myeloma. Selective inhibition has remained out of reach due to high homology with its paralog CBP.

NXO-001: first-in-class selective p300 inhibitor designed to avoid the toxicities associated with targeting both p300 and CBP.

One of cancer’s most prominent oncogenes and one of the most elusive targets for small molecule drug discovery.

We are developing a first-in-class, oral small molecule that directly targets β-catenin.

A master regulator of IL-1 and TLR signaling that drives inflammatory disease and has long been considered undruggable.

We are developing a first-in-class, direct-acting MyD88 inhibitor with biologic-like activity in an oral small molecule.